Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor.
Peter M AndersonMatteo M TruccoRohinton S TaraporeStefanie M ThomasStefanie ThomasJanette GortzOmar Y MianMartin StoignewVarun PrabhuSara MorrowJoshua E AllenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Oral ONC201 was well tolerated in patients with metastatic neuroendocrine tumors and associated with clinical benefit, including tumor responses, particularly in some patients with DSRCT and the majority of patients with PC-PG. See related commentary by Owen and Trikalinos, p. 1748.